Age-associated leukoaraiosis and cortical cholinergic deafferentation

Neurology

Volumn 72, Issue 16, 2009, Pages 1411-1416

  Bohnen, N I ^a,b   Miiller, M L T M ^a   Kuwabara, H ^c   Constantine, G M ^d   Studenski, S A ^e,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; METHYL 4 PIPERIDINYL PROPIONATE; UNCLASSIFIED DRUG; ACETYLCHOLINE; BIOLOGICAL MARKER;

ADULT; AGED; AGING; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEAFFERENTATION; DISEASE SEVERITY; FEMALE; FLAIR IMAGING; FOREBRAIN; HUMAN; IN VIVO STUDY; LEUKOARAIOSIS; MALE; NERVE FIBER GROWTH; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE SPECIFICITY; WHITE MATTER; WHITE MATTER HYPERINTENSITY; BRAIN CORTEX; METABOLISM; MEYNERT BASAL NUCLEUS; MIDDLE AGED; NERVE TRACT; PATHOLOGY; PATHOPHYSIOLOGY; SCINTISCANNING; SYNAPTOSOME;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; AGING; BASAL NUCLEUS OF MEYNERT; BIOLOGICAL MARKERS; CEREBRAL CORTEX; CHOLINERGIC FIBERS; COGNITION DISORDERS; FEMALE; HUMANS; LEUKOARAIOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURAL PATHWAYS; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS;

EID: 67449110909     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a187c6     Document Type: Article

References (31)

1. Schmidt R, Fazekas F, Offenbacher H, et al. Neuropsychologic correlates of MRI white matter hyper intensities: a study of 150 normal volunteers. Neurology 1993;43:2490-2494.
2. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis. Stroke 1997;28:652-659.
3. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216-240.
4. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249-2257.
5. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADA-SIL. Neurology 2003;60:1183-1185.
6. Cham R, Perera S, Studenski SA, Bohnen NI. Striatal dopamine denervation and sensory integration for balance in middle-aged and older adults. Gait Posture 2007;26:516-525.
7. Conners CK. The computerized continuous performance test. Psychopharmacol Bull 1985;21:891-892.
8. Reitan R. Validity of the Trail-making Tests as an indication of organic brain damage. Mot Skills 1958;8:271-276.
9. Scheltens P, Barkhof F, Leys D, et al. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
10. Kapeller P, Barber R, Vermeulen RJ, et al. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 2003;34: 441-445.
11. Bocti C, Swartz RH, Gao FQ, Sahlas DJ, Behl P, Black SE. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 2005;36:2126-2131.
12. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994;21:801-808.
13. Shute CC, Lewis PR. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. Z Zellforsch MikroskAnat 1966;69:334-343.
14. 11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998;25:751-754.
15. Weinhard K. Applications of 3D PET. In: Bendriem B, Townsend DW, eds. The Theory and Practice of 3D PET. Boston: Kluwer Academic Publishers; 1998:133-167.
16. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003;19:224-247.
17. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198.
18. Ashburner J, Friston KJ. Rigid body registration. In: Frack-owiak RSJ, Friston KL, Frith CD, et al, eds. Human Brain Function, 2nd ed. San Diego: Academic Press; 2003:1-24.
19. Frouin V, Comtat C, Reilhac A, Gregoire MC. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. J Nucl Med 2002; 43:1715-1726.
20. 18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects. Synapse 2000;37:81-89.
21. 11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001;21: 1354-1366.
22. 11C]PMP and PET. J Nucl Med 2008;49:118P.
23. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50-55.
24. Barkhof F, Scheltens P. Is the whole brain periventricular? J Neurol Neurosurg Psychiatry 2006;77:143-144.
25. Pawlak M, Krejza J. A new visual scale to assess white matter hyperintensities within cholinergic pathways. Stroke 2005;36:2064-2065.
26. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997;277:813-817.
27. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintenshies matter? J Stroke Cerebrovasc Dis 2003;12:29-36.
28. Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyper in tensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol 2008;65:1202-1208.
29. Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci 2007;62:83-85.
30. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 2005;380:127-132.
31. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253:242-247.